US Stock MarketDetailed Quotes

YMAB Y-mAbs Therapeutics

Watchlist
  • 6.160
  • -0.020-0.32%
Close Jan 17 16:00 ET
275.90MMarket Cap-11.41P/E (TTM)

Y-mAbs Therapeutics Key Stats

Y-mAbs Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 24.373M--
--2024/Q4-- / 26.944M--
Nov 8, 20242024/Q318.461M / 23.263M--
Aug 12, 20242024/Q222.798M / 23.019M--
May 7, 20242024/Q119.931M / 22.220M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 24.373M--
--2024/Q4-- / 26.944M--
Nov 8, 20242024/Q318.461M / 23.263M--
Aug 12, 20242024/Q222.798M / 23.019M--
May 7, 20242024/Q119.931M / 22.220M--

Unlock Free Earnings Estimates

Y-mAbs Therapeutics Earnings Reports

Read more

Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Jan 20, 2025

Buy

  • Buy

    75.00%
  • Hold

    12.50%
  • Sell

    12.50%

Price Target

No Data